{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:32:35Z","timestamp":1784946755407,"version":"3.55.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009577","name":"Lasker Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Post-transplantation cyclophosphamide (PTCy) reduces the incidence and severity of graft-versus-host disease (GVHD), thereby improving the safety and accessibility of allogeneic hematopoietic cell transplantation (HCT). We have shown that PTCy works by inducing functional impairment and suppression of alloreactive T cells. We also have identified that reduced proliferation of alloreactive CD4<jats:sup>+<\/jats:sup> T cells at day +7 and preferential recovery of CD4<jats:sup>+<\/jats:sup>CD25<jats:sup>+<\/jats:sup>Foxp3<jats:sup>+<\/jats:sup> regulatory T cells (T<jats:sub>regs<\/jats:sub>) at day +21 are potential biomarkers associated with optimal PTCy dosing and timing in our B6C3F1\u2192B6D2F1 MHC-haploidentical murine HCT model. To understand whether the effects of PTCy are unique and also to understand better the biology of GVHD prevention by PTCy, here we tested the relative impact of cyclophosphamide compared with five other optimally dosed chemotherapeutics (methotrexate, bendamustine, paclitaxel, vincristine, and cytarabine) that vary in mechanisms of action and drug resistance. Only cyclophosphamide, methotrexate, and cytarabine were effective in preventing fatal GVHD, but cyclophosphamide was superior in ameliorating both clinical and histopathological GVHD. Flow cytometric analyses of blood and spleens revealed that these three chemotherapeutics were distinct in constraining conventional T-cell numerical recovery and facilitating preferential T<jats:sub>reg<\/jats:sub> recovery at day +21. However, cyclophosphamide was unique in consistently reducing proliferation and expression of the activation marker CD25 by alloreactive CD4<jats:sup>+<\/jats:sup>Foxp3<jats:sup>-<\/jats:sup> conventional T cells at day +7. Furthermore, cyclophosphamide restrained the differentiation of alloreactive CD4<jats:sup>+<\/jats:sup>Foxp3<jats:sup>-<\/jats:sup> conventional T cells at both days +7 and +21, whereas methotrexate and cytarabine only restrained differentiation at day +7. No chemotherapeutic selectively eliminated alloreactive T cells. These data suggest that constrained alloreactive CD4<jats:sup>+<\/jats:sup>Foxp3<jats:sup>-<\/jats:sup> conventional T-cell numerical recovery and associated preferential CD4<jats:sup>+<\/jats:sup>CD25<jats:sup>+<\/jats:sup>Foxp3<jats:sup>+<\/jats:sup> T<jats:sub>reg<\/jats:sub> reconstitution at day +21 may be potential biomarkers of effective GVHD prevention. Additionally, these results reveal that PTCy uniquely restrains alloreactive CD4<jats:sup>+<\/jats:sup>Foxp3<jats:sup>-<\/jats:sup> conventional T-cell proliferation and differentiation, which may explain the superior effects of PTCy in preventing GVHD. Further study is needed to determine whether these findings also hold true in clinical HCT.<\/jats:p>","DOI":"10.3389\/fimmu.2022.796349","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T07:47:34Z","timestamp":1644911254000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation"],"prefix":"10.3389","volume":"13","author":[{"given":"Ashley D.","family":"Hadjis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia S.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzay M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle E.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra de Paula","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Venzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Eckhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Kanakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1997.15.5.1767","article-title":"Results of Allogeneic Bone Marrow Transplants for Leukemia Using Donors Other Than HLA-Identical Siblings","volume":"15","author":"Szydlo","year":"1997","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nrclinonc.2015.234","article-title":"Modern Approaches to HLA-Haploidentical Blood or Marrow Transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ Regulatory T Cells are Necessary for Posttransplantation Cyclophosphamide-Mediated Protection Against GVHD in Mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124218","article-title":"Post-Transplantation Cyclophosphamide Prevents Graft-Versus-Host Disease by Inducing Alloreactive T Cell Dysfunction and Suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.09.030","article-title":"Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation","volume":"26","author":"Wachsmuth","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.535","article-title":"Mechanisms of CD8+ T-Cell Resistance to Post-Transplantation Cyclophosphamide (PTCy)","volume":"25","author":"Patterson","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and Cancer: Golden Anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e974393","DOI":"10.4161\/2162402X.2014.974393","article-title":"Situational Aldehyde Dehydrogenase Expression by Regulatory T Cells may Explain the Contextual Duality of Cyclophosphamide as Both a Pro-Inflammatory and Tolerogenic Agent","volume":"4","author":"Kanakry","year":"2015","journal-title":"Oncoimmunology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746060-00001","article-title":"Expression of Adenosine Triphosphate-Binding Cassette (ABC) Drug Transporters in Peripheral Blood Cells: Relevance for Physiology and Pharmacotherapy","volume":"46","author":"K\u00f6ck","year":"2007","journal-title":"Clin Pharmacokinetics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2011.11.033","article-title":"Aldehyde Dehydrogenases and Cell Proliferation","volume":"52","author":"Muzio","year":"2012","journal-title":"Free Radical Biol Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug Resistance in Cancer: Role of ATP\u2013Dependent Transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2016.03.001","article-title":"ABC Transporters as Mediators of Drug Resistance and Contributors to Cancer Cell Biology","volume":"26","author":"Fletcher","year":"2016","journal-title":"Drug Resist Update"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2013.04.005","article-title":"The Role of Aldehyde Dehydrogenase (ALDH) in Cancer Drug Resistance","volume":"67","author":"Januchowski","year":"2013","journal-title":"BioMed Pharmacother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197104000-00004","article-title":"The Effect of Cytotoxic Drugs on Graft-Versus-Host Disease in Mice","volume":"11","author":"Owens","year":"1971","journal-title":"Transplantation"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14034","article-title":"Post-Transplant Bendamustine Reduces Gvhd While Preserving Gvl in Experimental Haploidentical Bone Marrow Transplantation","volume":"174","author":"Stokes","year":"2016","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.20","article-title":"Progressive Substitution of Posttransplant Cyclophosphamide With Bendamustine: A Phase I Study in Haploidentical Bone Marrow Transplantation","volume":"1","author":"Katsanis","year":"2020","journal-title":"eJHaem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.032","article-title":"Graft-Versus-Host Disease Prophylaxis With Post-Transplantation Bendamustine in Patients With Refractory Acute Leukemia: A Dose-Ranging Study","volume":"27","author":"Moiseev","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601363","article-title":"Beijnen JH. P-Glycoprotein and Mrp1 Collectively Protect the Bone Marrow From Vincristine-Induced Toxicity","volume":"89","author":"van Tellingen","year":"2003","journal-title":"vivo Br J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106351","article-title":"Disulfiram\/Cytarabine Eradicates a Subset of Acute Myeloid Leukemia Stem Cells With High Aldehyde Dehydrogenase Expression","volume":"92","author":"Yang","year":"2020","journal-title":"Leukemia Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-03-4062","article-title":"Mechanism of the Pharmacokinetic Interaction Between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions","volume":"64","author":"Breedveld","year":"2004","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.dmpk-13-rv-119","article-title":"Molecular Basis for Pharmacokinetics and Pharmacodynamics of Methotrexate in Rheumatoid Arthritis Therapy","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0215(19960301)65:5<613::Aid-ijc10>3.0.Co;2-8","article-title":"Involvement of MDR1 P-Glycoprotein in Multifactorial Resistance to Methotrexate","volume":"65","author":"Norris","year":"1996","journal-title":"Int J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1984","article-title":"Targeting Multidrug Resistance in Cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat Rev Drug Discovery"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the Role of ABC Transporters in Multidrug-Resistant Cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3904645","article-title":"Aldehyde Dehydrogenases: Not Just Markers, But Functional Regulators of Stem Cells","volume":"2019","author":"Vassalli","year":"2019","journal-title":"Stem Cells Int"},{"key":"B27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10549-011-1692-y","article-title":"Inhibition of Aldehyde Dehydrogenase (ALDH) Activity Reduces Chemotherapy and Radiation Resistance of Stem-Like Aldhhicd44\u207a Human Breast Cancer Cells","volume":"133","author":"Croker","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0125454","DOI":"10.1371\/journal.pone.0125454","article-title":"Aldehyde Dehydrogenase 1 (ALDH1) is a Potential Marker for Cancer Stem Cells in Embryonal Rhabdomyosarcoma","volume":"10","author":"Nakahata","year":"2015","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biopha.2007.04.011","article-title":"Role of Xenobiotic Efflux Transporters in Resistance to Vincristine","volume":"62","author":"Huang","year":"2008","journal-title":"Biomedicine Pharmacother"},{"key":"B30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/tpj.2013.11","article-title":"Genetic Variants Associated With Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results From the Treatment of Early Aggressive Rheumatoid Arthritis Trial","volume":"14","author":"Aslibekyan","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0205657","DOI":"10.1371\/journal.pone.0205657","article-title":"In Vitro Transport of Methotrexate by Drosophila Multidrug Resistance-Associated Protein","volume":"13","author":"Karasik","year":"2018","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199606000-00007","article-title":"Bendamustine Hydrochloride Activity Against Doxorubicin-Resistant Human Breast Carcinoma Cell Lines","volume":"7","author":"Strumberg","year":"1996","journal-title":"Anti-Cancer Drugs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.12.042","article-title":"and Their Role in Nucleoside and Nucleotide Drug Resistance","volume":"83","author":"Fukuda","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/sonc.2002.34872","article-title":"Metabolism and Mechanisms of Action of Bendamustine: Rationales for Combination Therapies","volume":"29","author":"Gandhi","year":"2002","journal-title":"Semin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.exphem.2013.03.004","article-title":"Acquired Resistance of Leukemic Cells to Arac is Associated With the Upregulation of Aldehyde Dehydrogenase 1 Family Member A2","volume":"41","author":"Kawasoe","year":"2013","journal-title":"Exp Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.041228","article-title":"Dose-Dependent Disposition of Methotrexate in Abcc2 and Abcc3 Gene Knockout Murine Models","volume":"39","author":"Wang","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701824569","article-title":"Mechanisms of Antifolate Resistance and Methotrexate Efficacy in Leukemia Cells","volume":"49","author":"Fotoohi","year":"2008","journal-title":"Leukemia Lymphoma"},{"key":"B38","article-title":"Mechanisms of Methotrexate Resistance in Osteosarcoma","volume":"5","author":"Guo","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/1042819032000159861","article-title":"Problems Related to Resistance to Cytarabine in Acute Myeloid Leukemia","volume":"45","author":"Cros","year":"2004","journal-title":"Leukemia Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-07-5528","article-title":"Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells","volume":"68","author":"Cai","year":"2008","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200600308","article-title":"Paclitaxel and Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes","volume":"2","author":"Galletti","year":"2007","journal-title":"ChemMedChem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.10.041","article-title":"New Insights Into Vinca Alkaloids Resistance Mechanism and Circumvention in Lung Cancer","volume":"96","author":"Zhang","year":"2017","journal-title":"Biomedicine Pharmacother"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206934","article-title":"Mechanisms of Taxol Resistance Related to Microtubules","volume":"22","author":"Orr","year":"2003","journal-title":"Oncogene"},{"key":"B44","article-title":"Cyclophosphamide Resistance in Medulloblastoma","volume":"52","author":"Friedman","year":"1992","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/1961110a0","article-title":"Prevention of Delayed Foreign Marrow Reaction in Lethally Irradiated Mice by Early Administration of Methotrexate","volume":"196","author":"Lochte","year":"1962","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1182\/blood.V66.3.698.698","article-title":"Marrow Transplantation for Chronic Myelocytic Leukemia: A Controlled Trial of Cyclosporine Versus Methotrexate for Prophylaxis of Graft-Versus-Host Disease","volume":"66","author":"Storb","year":"1985","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198603203141201","article-title":"Methotrexate and Cyclosporine Compared With Cyclosporine Alone for Prophylaxis of Acute Graft Versus Host Disease After Marrow Transplantation for Leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"New Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199310213291703","article-title":"Cyclosporine, Methotrexate, and Prednisone Compared With Cyclosporine and Prednisone for Prophylaxis of Acute Graft-Versus-Host Disease","volume":"329","author":"Chao","year":"1993","journal-title":"New Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s1083-8791(00)70007-3","article-title":"Equivalence of 2 Effective Graft-Versus-Host Disease Prophylaxis Regimens: Results of a Prospective Double-Blind Randomized Trial","volume":"6","author":"Chao","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10431","article-title":"Pharmacokinetic-Pharmacodynamic Modeling of Methotrexate-Induced Toxicity in Mice","volume":"92","author":"Lobo","year":"2003","journal-title":"J Pharm Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.11.025","article-title":"Treatment of Acute Leukemia With Unmanipulated HLA-Mismatched\/Haploidentical Blood and Bone Marrow Transplantation","volume":"15","author":"Huang","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B52","article-title":"The Pharmacological Phenotype of Combined Multidrug-Resistance Mdr1a\/1b- and Mrp1-Deficient Mice","volume":"61","author":"Johnson","year":"2001","journal-title":"Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jconrel.2004.06.018","article-title":"Poly(N-Vinylpyrrolidone)-Block-Poly(D,L-Lactide) as a New Polymeric Solubilizer for Hydrophobic Anticancer Drugs: In Vitro and In Vivo Evaluation","volume":"99","author":"Le Garrec","year":"2004","journal-title":"J Controlled release: Off J Controlled Release Soc"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0449-0","article-title":"Novel Biocompatible Intraperitoneal Drug Delivery System Increases Tolerability and Therapeutic Efficacy of Paclitaxel in a Human Ovarian Cancer Xenograft Model","volume":"60","author":"Vassileva","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"B55","article-title":"Toxicity Studies in Mice Treated With 1-Beta-D-Arabinofuranosylcytosine (Ara-C)","volume":"29","author":"Leach","year":"1969","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.mrgentox.2008.11.007","article-title":"Cytosine Arabinoside-Induced Cytogenotoxicity in Bone Marrow and Spermatogonial Cells of Mice and its Potential Transmission Through the Male Germline","volume":"673","author":"Palo","year":"2009","journal-title":"Mutat Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198809000-00024","article-title":"Dependency of Cyclophosphamide-Induced Skin Allograft Tolerance on Age of Adult Recipient Mice","volume":"46","author":"Mayumi","year":"1988","journal-title":"Transplantation"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.169.1.213%JJournalofExperimentalMedicine","article-title":"Long-Lasting Skin Allograft Tolerance in Adult Mice Induced Across Fully Allogeneic (Multimajor H-2 Plus Multiminor Histocompatibility) Antigen Barriers by a Tolerance-Inducing Method Using Cyclophosphamide","volume":"169","author":"Mayumi","year":"1989","journal-title":"J Exp Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0171-2985(89)80053-1","article-title":"The Necessity of Both Allogeneic Antigens and Stem Cells for Cyclophosphamide-Induced Skin Allograft Tolerance in Mice","volume":"178","author":"Mayumi","year":"1989","journal-title":"Immunobiology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S0171-2985(96)80033-7","article-title":"Cyclophosphamide-Induced Immunological Tolerance: An Overview","volume":"195","author":"Mayumi","year":"1996","journal-title":"Immunobiology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of Graft-Versus-Host Disease Prevention by Post-Transplantation Cyclophosphamide: An Evolving Understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146997","article-title":"Phase I\/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) After HLA-Haploidentical Bone Marrow Transplantation","volume-title":"Ash Annual Meeting & Exposition","author":"McAdams","year":""},{"key":"B63","first-page":"21","article-title":"Cyclosporine Plus Methylprednisolone as Prophylaxis for Graft-Versus-Host Disease: A Randomized Double-Blind Study in Patients Undergoing Allogeneic Marrow Transplantation","volume":"1","author":"Santos","year":"1987","journal-title":"Clin Transplant"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197003000-00007","article-title":"Methotrexate Regimens for Control of Graft-Versus-Host Disease in Dogs With Allogeneic Marrow Grafts","volume":"9","author":"Storb","year":"1970","journal-title":"Transplantation"},{"key":"B65","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/00007890-197301000-00014","article-title":"Marrow Grafts Between Dl-a-Matched Canine Littermates","volume":"15","author":"Storb","year":"1973","journal-title":"Transplantation"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.6.1729.1729","article-title":"Methotrexate and Cyclosporine Versus Cyclosporine Alone for Prophylaxis of Graft-Versus-Host Disease in Patients Given HLA-Identical Marrow Grafts for Leukemia: Long-Term Follow-Up of a Controlled Trial","volume":"73","author":"Storb","year":"1989","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444879","article-title":"Human Regulatory T Cells Lack the Cyclophosphamide-Extruding Transporter ABCB1 and are More Susceptible to Cyclophosphamide-Induced Apoptosis","volume":"44","author":"Dimeloe","year":"2014","journal-title":"Eur J Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000775","article-title":"Haploidentical Hematopoietic Cell and Kidney Transplantation for Hematological Malignancies and End-Stage Renal Failure","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000000605","article-title":"Immune Reconstitution\/Immunocompetence in Recipients of Kidney Plus Hematopoietic Stem\/Facilitating Cell Transplants","volume":"99","author":"Leventhal","year":"2015","journal-title":"Transplantation"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.796349\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T07:47:43Z","timestamp":1644911263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.796349\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":69,"alternative-id":["10.3389\/fimmu.2022.796349"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.796349","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"article-number":"796349"}}